Skip To Main Content
Abelardo Bárez on Muck Rack

Abelardo Bárez

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Abelardo

Contact Abelardo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The mutational landscape of resistance to BTK and BCL2 inhibitors in CLL: a real-world multicentric study

|
By Miguel Bastos-Boente, María García-Álvarez, Cristina Jimenez, María Eugenia Sarasquete, Alejandro Medina, Rebeca Maldonado, Maria Vidal Verified, María Vidal Verified, Luis Garcia, Carlos Aguilar, Cristina De Ramón, Norma Gutierrez, Ramón García-Sanz, Marcos Gonzalez, Marcos González Verified, Almudena Navarro-Bailón, Miguel Alcoceba, Alicia Antón, Ana Balanzategui, David Alonso-Castronuño, Erik de Cabo, Beatriz González-Mena, José María Alonso-Alonso, Emilia Pardal, Francisco Javier Díaz-Gálvez, José A. Queizán, María Jesús Peñarrubia, Abelardo Bárez
| Nature Verified
Abstract Resistance mechanism to BTK and BCL2 inhibitors in CLL remains poorly characterized, particularly regarding clonal dynamics and compartment-specific evolution. We analyzed 114 samples from 101 patients discontinuing therapy due to progression, toxicity, or Richter transformation using a 33-gene NGS panel. Notably, 34% of relapsed/refractory patients lacked BTK/PLCG2 mutations, a proportion that increased to 71% when considering only clonal alterations (VAF > 25%).
Open in Who Shared Issue with article?
See all 1 articles